Navigation Links
ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
Date:3/25/2009

of one or more of its product candidate programs, a strategic business merger and other transactions that maximize the value of the Company's assets. In January and March 2009, the Company announced headcount reductions and cost containment measures to provide additional time to consummate a strategic transaction. More information can be found on the Company's web site at www.adventrx.com.

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX will be unable to consummate a strategic or partnering transaction or raise sufficient capital to continue as a going concern; the risk that the Company's recent cost-cutting measures, including those announced on March 20, 2009, will negatively impact the Company's ability to consummate a strategic transaction; the risk that the Company will be unable to consummate a strategic or partnering transaction or raise sufficient capital and will be unable to continue as a going concern; the risk that the departure of the Company's former Chief Executive Officer and President, the Company's Executive Vice President and Chief Financial Officer and/or the Company's leadership by a committee of executive officers will negatively impact the Company's ability to consummate a strategic transaction or to maintain effective disclosure controls and procedures or internal control over financial reporting; the risk that the Company's stockholders will not approve a strategic or capital-raising transaction recommended by the C
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ADVENTRX Announces Further Cost-Cutting Measures
2. ADVENTRX Provides Update on Strategic Transaction Process
3. ADVENTRX Announces Further Cost-Cutting Measures
4. ADVENTRX Exploring Strategic Options
5. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
6. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
7. ADVENTRX Announces Restructuring and Cost Reduction Initiatives
8. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
9. ADVENTRX Settles Dispute With Former Licensee
10. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
11. ADVENTRX Appoints Vice President of Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 2015  Faced with increasing challenges such as ... than symptomatic, the global healthcare industry today is ... of curing or significantly changing the course of ... towards regenerative medicine as a viable alternative. ... human health with the potential to resolve unmet ...
(Date:7/27/2015)... , ... July 27, 2015 , ... Production of high ... the past few years in the EU. For instance, it surpassed the EUR 106 ... 92 million mark in 2010. Germany is a major producer, while Italy is a ...
(Date:7/27/2015)... -- According to the new Market Research Report ... by Application (Biobanking, Regenerative Medicine, Drug Discovery), by Geography ( ... Asia-Pacific , Rest of the World) - ... was valued at $247.7 million in 2014, which is estimated ... CAGR of 18.2% between 2014 and 2019. Browse ...
(Date:7/26/2015)... Cumberland, Maine (PRWEB) , ... July 26, 2015 ... ... the release of its VALIDATE® ANEMIA calibration verification / linearity test kit. The ... matrix. Each VALIDATE® ANEMIA kit is prepared using the CLSI recommended “equal ...
Breaking Biology Technology:Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2
... DIEGO, Jan. 29 BioMed Realty Trust, Inc.,(NYSE: BMR ... quarter,and year ended December 31, 2007 after the market closes ... Chief Executive Officer, and Kent Griffin,Chief Financial Officer, will host ... February 29, 2008 to discuss the company,s,financial results and operations ...
... Jan. 29 QED International Associates, Inc,administrator ... 20 underlying,indexes for the HealthShares(TM) Exchange-Traded Funds, ... trading on Thursday January 31, 2008 KV,Pharmaceutical ... (Nasdaq: ARXT ) in the HealthShares(TM) ...
... to be Highlighted at Molecular Imaging Conference, ... Inc., (OTC Bulletin Board: IMDS) a pioneer in ... 2008, January 28 - 31,2008, in Dubai, United ... CD89., (Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO ), ...
Cached Biology Technology:BioMed Realty Trust To Report 2007 Fourth Quarter and Year-End Results 2QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Respiratory/Pulmonary Indexes 2Imaging Diagnostic Systems Exhibits at Major Middle East Health Conference 2Imaging Diagnostic Systems Exhibits at Major Middle East Health Conference 3
(Date:6/30/2015)... , June 30, 2015 To bolster its efforts ... HYPR Corp. announced today the addition of two new team ... as board advisor and David Raviv will act ... underscore HYPR Corp.,s commitment to providing the most secure solutions ... Sirota co-founded Layer 7 Technologies, a provider of security ...
(Date:6/26/2015)... SPRINGVILLE, Utah , June 26, 2015 ATL ... assemblies and devices with specialties in single use solutions, headquartered ... acquisition of MedConx, Inc. (a California ... , and San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing ...
(Date:6/25/2015)...  TAKE Solutions Ltd., a global business technology solutions ... Patent and Trademark Office (USPTO) for its "Method for ... Clinical Accelerators to reduce the time taken to standardize ... without the accelerators), thus reducing time to market. ... the heart of the patented Clinical Data Standardization Process ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2
... menace stalks the loons, gulls and other water birds of ... caused when birds eat fish infected with toxin-producing bacteria. Cases ... more waterfowl in 2007 than when it was first reported ... ocean engineers from the Florida Atlantic University (FAU) Institute for ...
... State University allows scientists to zoom in on the ... scientists to see the structure of microorganisms, cells, metals, ... light microscopes. But while these images have allowed scientists ... function could only be estimated because of static images. ...
... engineering and bioengineering who joined the Erik Jonsson School ... recipient of a $2.3 million grant from the National ... control theory and physical rehabilitation to revolutionize and improve ... American Society of Mechanical Engineers report ,2028 Vision for ...
Cached Biology News:Great lakes waterfowl die-offs: Finding the source 2New microscope captures movements of atoms and molecules 2UT Dallas professor wins $2.3 million NIH award 2UT Dallas professor wins $2.3 million NIH award 3
RayBio L Series 507: RayBio Label-based Antibody Array I (2 membranes) Class: Antibody Array Products Product Group: Antibody Array...
... template DNA, primers, salts or other unwanted ... proved critical for both standard and capillary ... with dye terminator cycle sequencing chemistries such ... uniformity of the magnetic paeticles guarantees consistent ...
Human HVEM/TNFRSF14 Allophycocyanin MAb (Clone 94801)...
Mature rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and processed within 45 minutes. It is then filtered through gauze, pooled in an ...
Biology Products: